See the DrugPatentWatch profile for cosentyx

Based on the available information, there is no explicit recommendation for or against administering the MMR (measles, mumps, and rubella) vaccine during Cosentyx (secukinumab) treatment. It is crucial to consult with a healthcare provider for personalized medical advice.

When considering vaccinations during biologic therapy, several factors come into play, such as the patient's overall health, the specific biologic medication, and the type of vaccine. Biologics like Cosentyx, which target specific components of the immune system, may impact vaccine effectiveness and potential side effects [1].

Cosentyx is a monoclonal antibody that specifically inhibits interleukin-17A (IL-17A), a cytokine involved in inflammatory and immune responses [2]. Although there is no specific information on MMR vaccine interactions with Cosentyx, live-virus vaccines like MMR might pose a risk during biologic therapy due to the temporarily weakened immune system [1].

Considering DrugPatentWatch.com, Cosentyx's patent expiration is expected in 2024, which may lead to the introduction of biosimilars [3]. However, this information does not directly address the question of MMR vaccine administration during Cosentyx treatment.

In summary, consult a healthcare provider to determine the safety and efficacy of the MMR vaccine during Cosentyx treatment, as individual patient circumstances and medical history will influence the decision.

Sources:

1. Centers for Disease Control and Prevention. (2019). Vaccination of persons with weakened immune systems (immunocompromised persons). <https://www.cdc.gov/vaccines/recommendations/immunocompromised-hosts/index.html>
2. Novartis. (n.d.). Cosentyx (secukinumab) prescribing information. <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf>
3. DrugPatentWatch.com. (n.d.). Secukinumab (Cosentyx). <https://www.drugpatentwatch.com/drugs/secukinumab>